Interestingly, patients with specific mutations in SLC15A2 (encoding Pept2) have a longer progression-free survival against hepatocellular carcinoma when treated with sorafenib (Lee et al., 2015b; Minhas and Newstead, 2019). Here, SLC15A2 is linked to hepatocellular carcinoma.